Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 4c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q2 EPS of ($0.28), $0.04 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM